Vector-mediated drug delivery to the brain

Bibliography

• EHRLICH P: Das Sauerstoff-Bedürfniss des Organismus: Eine farbenanalytische Studie, Hirschwald, Berlin (1885).
   Google Scholar
• BRIGHTMAN MW: Morphology of blood-brain interfaces. Exp. Eye. Res. (1977) 25:1–25.
   PubMed Web of Science ®Google Scholar
• JANZER RC, RAFF MC: Astrocytes induce blood-brain barrier properties in endothelial cells. Nature (1987) 325:253–257.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN GW, BETZ AL: Specialized properties and solute transport in brain capillaries. Ann. Neural. (1986) 14:389–395.
   Google Scholar
• RAPOPORT SI: Modulation of blood-brain barrier permeability. j Drug Target (1996) 3:417–425.
   PubMed Web of Science ®Google Scholar
• TAMAI I, TSUJI A: Drug delivery through the blood-brain barrier. Advan. Dug Delivery Rev (1996) 19:401–424.
   Web of Science ®Google Scholar
• PARDRIDGE WM: New approaches to drug delivery through the blood-brain barrier. Tibtech (1994) 12:239–245.
   PubMed Web of Science ®Google Scholar
• JOLLIET-RIANT P, TILLEMENT JP: Drug transfer across the blood-brain barrierand improvement of brain delivery. Fundam. Pharmacal. (1999) 13:16–26.
   PubMed Web of Science ®Google Scholar
• TEMSAMANI J, SCHERRMANN JM, REES AR et al.: Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharmac. Sci. Technol. Today (2000) 2:49–59.
   Google Scholar
• ABBOTT NJ, RE VEST PA: Control of brain endothelial permeability. Cerebrovasc. Brain Metab. Rev (1991) 3:39–72.
   PubMedGoogle Scholar
• GREENWOOD J: Physiology and Pharmacology of the Blood-brain barrier. In: Handbook of Experimental Pharmacology Bradbury MWB, Abbott NJ (Eds.), Springer-Verlag, Berlin (1992):459–486.
   Google Scholar
• RAPOPORT SI, OHNO K, PETTIGREW KD: Drug entry into the brain. Brain Res. (1979) 172:354–359.
   PubMed Web of Science ®Google Scholar
• LEVIN VA: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. j Med. Chem. (1980) 23:682–684.
   PubMed Web of Science ®Google Scholar
• TSUJI A, TAMAI I: Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Delivery Rev (1999) 36:277–290.
   PubMed Web of Science ®Google Scholar
• BANKS WA, KASTIN AJ, BARRER CM: Delivering peptides to the central nervous system: dilemmas and strategies. Pharm. Res. (1991) 8:1345–1350.
   PubMed Web of Science ®Google Scholar
• ZLOKOVIC BV: Cerebrovascular permeability to peptides: manipulations of transport system at the BBB. Pharm. Res. (1995) 12:1395–1406.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, TRIGUERO D, YANG J et al.: Composition of in vitro and in vivo models of drug transcytosis through the BBB. j Pharmacal. Esp. Ther. (1990) 253:884–891.
   PubMed Web of Science ®Google Scholar
• ANTONY AC: Folate receptors. Ann. Rev Num. (1996) 16:501–521.
   PubMed Web of Science ®Google Scholar
• BROAD WELL RD, BAKER-CAIRNS BJ,FRIDEN PM et al.: Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-born transferrin and antibody against the transferrin receptor. Exp. Neural. (1996) 142:47–65.
   Google Scholar
• FRANK HJ, PARDRIDGE WM, MORRIS WL et al.: Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes (1986) 35:654–661.
   PubMed Web of Science ®Google Scholar
• BOBO RH, LASKE DW, AKBASAK A et al.: Convection-enhanced delivery of macromolecules in the brain. Proc. Nati Acad. Li. USA (1994) 91:2076–2080.
   PubMed Web of Science ®Google Scholar
• KROLL RA, PAGEL MA, MULDOON LL et al.: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 38:746–754.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN DM, LASKE DW, MORRISON PF et al.: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion.Neurosurg. (1995) 82:1021–1029.
   Web of Science ®Google Scholar
• AIRD RB: A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp. Neurol. (1984) 86:342–358.
   PubMed Web of Science ®Google Scholar
• NEUWELT EA, RAPOPORT SI: Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. (1984) 43:214–219.
   PubMedGoogle Scholar
• KROLL RA, NEUWELT EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 42:1083–1099.
   PubMed Web of Science ®Google Scholar
• SALAHUDDIN TS, JOHANSSON BB, KALIMO H et al.: Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol. Appl. Neurobiol. (1988) 14:467–482.
   PubMed Web of Science ®Google Scholar
• SALAHUDDIN TS, JOHANSSON BB, KALIMO H et al.: Structural changes in therat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. (1988) 77:5–13.
   PubMed Web of Science ®Google Scholar
• BARTUS RT, ELLIOTT PJ, DEAN RL et al.: Controlled modulation of BBB permeability using the bradykinin agonist, RIVIP-7. Esp. Neurol. (1996) 142:14–28.
   PubMed Web of Science ®Google Scholar
• FORD J, OSBORN C, BARTON T et al.: A Phase I study of intravenous RIV1P-7 with carboplatin in patients with progression of malignant glioma. Eur. j Cancer (1998) 34:1807–1811.
   PubMed Web of Science ®Google Scholar
• EMERICH DF, SNODGRASS E PINK M et al.: Central analgesic actions of loperamide following transient permeation of the blood-brain barrier with Cereport (RIVIP-7). Brain Res. (1998) 801:259–266.
   Google Scholar
• GREIG NH: Drug delivery to the brain by blood-barrier: circumvention and drug modification. In: Implications of the blood-brain barrier and its manipulation. Neuwelt EA (Ed.) Plenum Press: New York. Vol 1 (1989):311–367.
   Google Scholar
• SAWYNOK J: The therapeutic use of heroin: a review of the pharmacological literature. Can. j Physiol. Pharmacol. (1986) 64:1–6.
   PubMed Web of Science ®Google Scholar
• BODOR N: Drug targeting and retrometabolic drug design approaches. Adv. Drug Deliv. Rev (1994) 14:157–166.
   Web of Science ®Google Scholar
• TSUZUKI N, HAMA T, KAWADA M et al.: Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. j Pharm. Sci. (1994) 83:4481–4484.
   Google Scholar
• CHEKHONIN VP, KABANOV AV, ZHIRKOV YA et al.: Fatty acid acylate Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain. FEBS Lett. (1991) 287:149–152.
   PubMed Web of Science ®Google Scholar
• SHASHOUA VE, HESSE GW: N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Li. (1996) 58:1347–1357.
   Google Scholar
• PATEL D, MCKINLEY BD, DAVIS TP et al.: Peptide targeting and delivery across the blood-brain barrier utilizing synthetic triglyceride esters: design, synthesis, and bioactivity. Bioconjug. Chem. (1997) 8:434–441.
   PubMed Web of Science ®Google Scholar
• JACOB JN, SHASHOUA VE, CAMPBELL A et al.: Gamma-aminobutyric acid esters. 2. Synthesis, brain uptake, and pharmacological properties of lipid esters of gamma-aminobutyric acid.Med. Chem. (1985) 28:106–110.
   Google Scholar
• PARDRIDGE WM: Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Deliv. Rev. (1995) 15:5–36.
   PubMed Web of Science ®Google Scholar
• POLT R, PORRECA F, SZABO LZ etal.: Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Nati Acad. Sci. USA (1994) 91:7114–7118.
   Google Scholar
• YOSHIKAWA T, SAKAEDA T, SUGAWARA T et al.: A novel chemical delivery system for brain targeting. Adv. Dug Deliv. Rev. (1999) 36:255–275.
   PubMed Web of Science ®Google Scholar
• KUMAGAI AK, EISENBERG JB, PARDRIDGE WM: Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. j Biol. Chem. (1987) 262:15214–15219.
   PubMed Web of Science ®Google Scholar
• BICKEL U, YOSHIKAWA T, LANDAW EM et al.: Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA (1993) 90:2618–2622.
   PubMed Web of Science ®Google Scholar
• ROUSSELLE C, CLAIR P, LEFAUCONNIER JM et al.: New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. (2000) 57:679–686.
   PubMed Web of Science ®Google Scholar
• ROUSSELLE C, SMIRNOVA M, CLAIR P et al.: Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. Pharmacol. Exp. Ther. (2001) 296:124–131.
   PubMed Web of Science ®Google Scholar
• SCHWARZE SR, HO A, VOCERO-AKBANI A etal.: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 285:1569–1572.
   Google Scholar
• PARDRIDGE WM, KANG YS, BUCIAK JL et al.: Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate.Pharm. Res. (1995) 12:807: 816.
   Google Scholar
• PARDRIDGE WM: Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharmac. Sci. Technol. Today (1999) 2:49–59.
   PubMedGoogle Scholar
• WU D, PARDRIDGE WM: Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. j Pharmacol. Exp. Ther. (1996) 279:77–83.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, BOADO RJ, KANG YS : Vector-mediated delivery of a polyamide (Peptide') nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA (1995) 92:5592–5596.
   PubMed Web of Science ®Google Scholar
• KANG YS, PARDRIDGE WM: Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm. Res. (1994) 11:1257–1264.
   PubMed Web of Science ®Google Scholar
• TRIGUERO D, BUCIAK JB, PARDRIDGE WM: Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. j Neurochem. (1990) 54:1882–1888.
   PubMed Web of Science ®Google Scholar
• TAMAI I, SAI Y, KOBAYASHI H et al.: Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. Pharmacol. Exp. Ther. (1997) 280:410–415.
   PubMed Web of Science ®Google Scholar
• TERASAKI T, DEGUCHI Y, SATO H et al.: In vivo transport of a dynorphin-like analgesic peptide, E-2078, through the blood-brain barrier: an application of brain microdialysis. Phann. Res. (1991) 8:815–820.
   PubMed Web of Science ®Google Scholar
• DEROSSI D, CHASSAING G, PRO CHIANTZ A: Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. (1998) 8:84–87.
   PubMed Web of Science ®Google Scholar
• HARWIG SS, SWIDEREK KM, LEE TD et al.: Determination of disulphide bridges in PG-2, an antimicrobial peptide from porcine leukocytes. j Pept. Sri. (1995) 1:207–215.
   PubMedGoogle Scholar
• AUMELAS A, MANGONI M, ROUMESTAND C et al.: Synthesis and solution structure of the antimicrobial peptide protegrin- 1. Eur. j Biochern. (1996) 237:575–583.
   PubMedGoogle Scholar
• MAZEL M, CLAIR E ROUSSELLE C et al.: Doxorubicin-peptide conjugates overcome multidrug resistance. Anti-Cancer Drugs (2001) 12:107–116.
   PubMed Web of Science ®Google Scholar
• FRIDEN PM, WALUS LR, MUSSO GF et al.: Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Li. USA (1991) 88:4771–4775.
   PubMed Web of Science ®Google Scholar
• FRIDEN PM, WALUS LR, WATSON P et al.: Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science (1993) 259:373–377.
   PubMed Web of Science ®Google Scholar
• WALUS LR, PARDRIDGE WM, STARZYK RIVI et al.: Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. Phannacol. Exp. Ther. (1996) 277:1067–1075.
   PubMed Web of Science ®Google Scholar
• LETVIN NL, CHALIFOUX LV, REIMANN KA et al.: In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. I Clin. Invest. (1986) 77:977–984.
   Google Scholar